

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 13824

**Title:** Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe

**Reviewer code:** 02445675

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2014-09-04 14:09

**Date reviewed:** 2014-09-27 01:15

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

I consider the paper suitable for publication on WJG.

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 13824

**Title:** Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe

**Reviewer code:** 00004485

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2014-09-04 14:09

**Date reviewed:** 2014-09-30 23:39

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

This manuscript is limited by the unknown accuracy of the true incidence and prevalence of CD and CUC in Eastern and Central Europe. Nevertheless, it is an important paper in defining and trying to explain the variability of biologic use in IBD. 1. Please comment on the frequency of biologic use for IBD in 1) Western Europe, and 2) the US, relative to Central and Eastern Europe. 2. "Presenteeism," page 8, is not a word in the English language. Please rephrase. Nor is "originator" infliximab a commonly accepted term. The reviewer understands the reluctance to call this "Remicade" or its translation. One might define this as the "TNF inhibitor initially released" or the "originally released TNF monoclonal antibody," or... 3. There are multiple grammar suggestions that the reviewer has made to improve the flow of this manuscript. 4. Please clarify whether the costs quoted for the biologic medications are a per dose cost or for an induction/maintenance therapy. Either way, these costs are dramatically less than those charged in the US.

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 13824

**Title:** Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe

**Reviewer code:** 02439579

**Science editor:** Ya-Juan Ma

**Date sent for review:** 2014-09-04 14:09

**Date reviewed:** 2014-10-09 15:51

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair		BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

Many references are with the incidence of IBD decades ago, and some are not nationwide studies, the manuscript is limited by the unknown accuracy of the true incidence and prevalence of IBD in Eastern and Central Europe. Nevertheless, it is an important paper in trying to explain the variability of biologic use in IBD.